Samsung BioLogics Co Ltd
Company Profile
Business description
Samsung BioLogics Co Ltd is a biopharmaceutical company engaged in drug development and manufacturing services. The company operates two segments: Biopharmaceutical Development and Commercialization, and Contract Development and Manufacturing Organization (CDMO). The Biopharmaceutical Development and Commercialization segment focuses on developing and commercializing biosimilars across therapeutic areas, including autoimmune, oncology, ophthalmology, and hematology. The Contract Development and Manufacturing Organization (CDMO) segment provides biopharmaceutical contract manufacturing along with cell line and process development services. It generates the majority of its revenue from the CDMO segment.
Contact
300, Songdo Bio-Daero
Yeonsu-Gu
Incheon21987
KORT: +82 324553114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5,273
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
stocks
What did Morningstar subscribers buy and sell during March?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.10 | 41.30 | -0.45% |
| CAC 40 | 8,305.41 | 69.43 | 0.84% |
| DAX 40 | 24,036.52 | 294.08 | 1.24% |
| Dow JONES (US) | 48,218.25 | 301.68 | 0.63% |
| FTSE 100 | 10,600.80 | 17.84 | 0.17% |
| HKSE | 25,872.32 | 211.47 | 0.82% |
| NASDAQ | 23,183.74 | 280.84 | 1.23% |
| Nikkei 225 | 57,877.39 | 1,374.62 | 2.43% |
| NZX 50 Index | 13,017.26 | 2.92 | -0.02% |
| S&P 500 | 6,886.24 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,970.80 | 43.20 | -0.48% |
| SSE Composite Index | 4,026.63 | 38.07 | 0.95% |